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Dengue vaccine: reliably determining previous exposure 
Dengue fever is the most prevalent and widespread 
mosquito-borne viral disease, and can only be countered 
by integrated prevention and control strategies, 
including sustained vector control programmes, the 
best evidence-based clinical care, and vaccination.
The first dengue vaccine, CYD-tetravalent dengue 
vaccine (CYD-TDV) or Dengvaxia (Sanofi Pasteur, Lyon, 
France), is licensed in 20 countries. Initial findings from 
two large phase 3 clinical trials have shown good but 
incomplete protection, in particular against severe dengue 
and dengue disease that requires hospital admission.1,2 
In November, 2017, Sanofi Pasteur announced the 
results from additional studies showing that the vaccine 
has a differential performance in individuals who have 
previously been infected by dengue virus (seropositive) 
versus those without previous dengue virus infection 
(seronegative).3 Vaccine efficacy against laboratory-
confirmed symptomatic dengue virus infection was high 
among individuals who were seropositive at baseline 
and aged at least 9 years (76%, 95% CI 63·9–84·0), but 
much lower among participants who were seronegative 
at baseline (38%, –0·9 to 62·9). Furthermore, vaccination 
of individuals who are seronegative increases their 
risk of severe dengue or dengue that requires hospital 
admission.4 Subsequently, in April, 2018, WHO’s Strategic 
Advisory Group of Experts recommended that in 
countries considering the introduction of vaccination with 
CYD-TDV, pre-vaccination screening should be preferred 
to assess dengue virus serostatus, and only people who 
are dengue seropositive should be vaccinated. To this end, 
WHO also encouraged the urgent development of rapid 
diagnostic tests (RDTs) to establish serostatus.
Because dengue viruses are of the genus Flavivirus, 
composed of genetically, structurally, and antigenically 
related viruses, such as Zika virus, yellow fever virus, 
and tick-borne encephalitis virus, antibody detection 
tests have high cross-reactivity and consequently poor 
reliability for the diagnosis of past dengue virus infection.5 
With large flavivirus-exposed populations in Latin 
America, Asia, and Africa, a rapidly growing population 
of travellers from and to endemic areas,6 and increased 
vaccination coverage against yellow fever virus, tick-
borne encephalitis virus, and Japanese encephalitis virus 
in travellers and in certain endemic regions, it is evident 
that establishing serostatus is extremely challenging.
Many commercial immunoglobulin (Ig)G-containing 
point-of-care tests (POCTs) and dengue IgG ELISA 
assays are available. For the purpose of pre-vaccination 
screening, the assay with the highest sensitivity and 
specificity would be the desirable option. Low sensitivity 
would result in under-vaccinating individuals who are 
truly seropositive and who would benefit from the 
vaccine, whereas low specificity would lead to falsely 
vaccinating people who are truly seronegative, putting 
them at risk of severe dengue during the next natural 
infection with dengue virus.
The plaque reduction neutralisation test (PRNT) 
is still considered the gold standard for establishing 
serostatus, but requires specific laboratory and 
technical capacity, and is labour intensive, costly, 
and time consuming. Although dengue IgG ELISA 
correlates reasonably well with the results of a PRNT, 
the test has a lower sensitivity and specificity than 
PRNT, although the studies7,8 that showed this lower 
sensitivity and specificity were done before Zika virus 
became a widespread problem in the Americas. Dengue 
IgG ELISA requires about 2·5 h of laboratory time, 
excluding the time needed for sample transportation 
to the laboratory, batch analysis, and reporting to the 
clinician, which requires two visits for the vaccinees. 
Point-of-care testing that uses RDTs provides the 
vaccine recipient with a result within 15–30 min, and 
can be done in an outpatient or outreach setting, such 
as schools and care facilities, using a finger prick sample. 
Thus, a decision on vaccination eligibility can be made 
during the same visit, thereby ensuring a reasonable 
vaccine uptake. POCTs generally have lower sensitivity 
and specificity than dengue IgG ELISAs. However, this 
low sensitivity and specificity needs to be weighed 
up against the faster speed of testing, lower cost, and 
improved accessibility outside specialised laboratories 
compared with IgG ELISAs.
As available RDTs were mainly developed for the 
purpose of diagnosing acute dengue virus infection, 
further efforts would be justified to fine-tune such RDTs 
to increase sensitivity and specificity for diagnosing 
serostatus. To increase the sensitivity of dengue RDTs 
to detect previous dengue virus infection, several 
modifications could be contemplated, one of which 
would be recalibration by changing the concentration 
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of the IgG capture antigen or detection reagent to 
lower the limit of anti-dengue IgG detection. To address 
cross-reactivity with other flaviviruses, particularly Zika, 
other modifications should be considered to improve 
specificity.
Diagnostic methods for flavivirus antibody detection 
use the entire virus particle, recombinant surface 
E-protein, or NS1 protein as antibody-capturing antigens. 
Epitopes with high aminoacid sequence homology 
among serotypes or flaviviruses can trigger cross-reactive 
responses, but type-specific antibodies directed towards 
unique E and NS1 epitopes are also raised.9,11 The art of 
making specific serological tests lies in the identification, 
selection, and presentation of those epitopes, either as 
recombinant protein fragments or peptides that only 
bind type-specific IgG, instead of using the entire virion or 
recombinant protein that contains both type-specific and 
cross-reactive antibody epitopes. Dengue virus antibody 
tests that use recombinant E-protein to absorb IgG will 
not be useful anymore for pre-testing purposes or for 
seroprevalence studies once the dengue vaccine (that 
uses dengue virus E-protein as an immunogen) is widely 
spread. Capturing type-specific non-E-protein-directed 
antibodies could be an alternative approach, as applied in 
the recently developed Zika virus-specific NS1 blockade-
of-binding ELISA.10 Comparative epitope modelling and 
genome-wide peptide microarray analysis can help to 
identify virus-specific epitopes targeted by antibodies 
in individuals who are flavivirus seropositive. Whereas 
obtaining type-specific epitopes is challenging but 
technically feasible, the difficulty might be in retaining 
sufficiently high sensitivity when aiming to detect specific 
subsets of antibodies in people who have been exposed 
to flavivirus. The epitope specificity and the abundance 
of such subsets of antibodies might also differ between 
populations and individuals as a result of differences 
in genetic background, co-circulating pathogens, 
vaccination, history of natural infection, and timing of 
sampling. Combining multiple type-specific epitopes and 
antigen–antibody crosslinking could potentially help 
address this issue. Evaluation platforms and access to well 
characterised samples to accelerate test development and 
access to market are urgently needed.
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